866-997-4948(US-Canada Toll Free)

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Oncology

No. of Pages : 435 Pages

This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Chronic Lymphocytic Leukemia (CLL) Overview 12
Therapeutics Development 13
Pipeline Products for Chronic Lymphocytic Leukemia (CLL) - Overview 13
Pipeline Products for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis 14
Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 15
Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 22
Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 25
Late Stage Products 25
Clinical Stage Products 26
Early Stage Products 27
Unknown Stage Products 28
Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 29
Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 35
Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 36
Bristol-Myers Squibb Company 36
F. Hoffmann-La Roche Ltd. 37
Amgen Inc. 38
Sanofi 39
Eli Lilly and Company 40
Viralytics Ltd. 41
Genentech, Inc. 42
MedImmune, LLC 43
Gilead Sciences, Inc. 44
Daiichi Sankyo Company, Limited 45
Emergent BioSolutions Inc. 46
Lentigen Corporation 47
Amorfix Life Sciences Ltd. 48
Piramal Enterprises Limited 49
Celltrion, Inc. 50
Astellas Pharma Inc. 51
BioMarin Pharmaceutical Inc. 52
Richter Gedeon Nyrt. 53
Astex Pharmaceuticals, Inc. 54
Genmab A/S 55
Cyclacel Pharmaceuticals Inc. 56
Celgene Corporation 57
Onyx Pharmaceuticals, Inc. 58
Bayer AG 59
Incyte Corporation 60
Merck KGaA 61
4SC AG 62
Celldex Therapeutics, Inc. 63
Immunomedics, Inc. 64
TG Therapeutics, Inc. 65
Portola Pharmaceuticals, Inc. 66
Mundipharma International Limited 67
Senesco Technologies, Inc. 68
Panacea Biotec Limited 69
Simcere Pharmaceutical Group 70
Hybrigenics S.A. 71
Spectrum Pharmaceuticals, Inc. 72
Memgen, LLC. 73
Hutchison MediPharma Limited 74
Altor BioScience Corporation 75
Arno Therapeutics, Inc. 76
Grupo Ferrer Internacional, S.A. 77
Onconova Therapeutics, Inc. 78
Angstrom Pharmaceuticals, Inc. 79
Tragara Pharmaceuticals, Inc. 80
Aprea AB 81
Biothera, Inc. 82
LFB Biotechnologies, S.A.S 83
KAEL-GemVax Co., Ltd. 84
Biosidus S.A. 85
Fountain Biopharma Inc. 86
Igenica, Inc. 87
Aprogen, Inc. 88
Karyopharm Therapeutics, Inc. 89
Vivia Biotech, S.L. 90
Lead Discovery Center GmbH 91
Kancera AB 92
Conkwest, Inc. 93
International Biotechnology Center Generium 94
MENTRIK Biotech, LLC 95
Rhizen Pharmaceuticals SA 96
bioXPRESS Therapeutics SA 97
Tolero Pharmaceuticals, Inc. 98
Innovent Biologics, Inc. 99
AbbVie Inc. 100
Epirus Biopharmaceuticals, Inc. 101
Amgen Astellas BioPharma K.K. 102
Senhwa Biosciences 103
Pharmapraxis 104
Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 105
Assessment by Monotherapy Products 105
Assessment by Combination Products 106
Assessment by Target 107
Assessment by Mechanism of Action 114
Assessment by Route of Administration 121
Assessment by Molecule Type 124
Drug Profiles 127
obinutuzumab - Drug Profile 127
idelalisib - Drug Profile 130
ofatumumab - Drug Profile 132
bendamustine hydrochloride RTD - Drug Profile 136
bendamustine hydrochloride - Drug Profile 137
lenalidomide - Drug Profile 138
cholecalciferol - Drug Profile 141
bendamustine - Drug Profile 142
alvocidib hydrocholride - Drug Profile 144
sorafenib tosylate - Drug Profile 145
vismodegib - Drug Profile 149
AT-7519 - Drug Profile 152
AR-42 - Drug Profile 155
otlertuzumab - Drug Profile 157
forodesine hydrochloride - Drug Profile 159
ISF-35 - Drug Profile 161
sapacitabine - Drug Profile 163
MEDI-551 - Drug Profile 165
A-6 - Drug Profile 167
ublituximab - Drug Profile 169
bevacizumab - Drug Profile 171
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 175
inecalcitol - Drug Profile 177
GS-9973 - Drug Profile 179
veltuzumab - Drug Profile 180
moxetumomab pasudotox - Drug Profile 183
milatuzumab - Drug Profile 185
SNS-01T - Drug Profile 187
SG-2000 - Drug Profile 189
ruxolitinib phosphate - Drug Profile 191
CD3/CD28 Activated T cells - Drug Profile 195
APR-246 - Drug Profile 196
IMMU-110 - Drug Profile 197
CD19CAR/Virus Specific T Cells - Drug Profile 199
ALT-803 - Drug Profile 200
PGG beta-glucan - Drug Profile 202
Minor Histocompatibility Antigen - Drug Profile 206
CDX-1127 - Drug Profile 207
4SC-202 - Drug Profile 208
SAR-650984 - Drug Profile 210
carfilzomib - Drug Profile 211
TG-02 - Drug Profile 214
tertomotide - Drug Profile 216
rigosertib sodium - Drug Profile 218
ulocuplumab - Drug Profile 221
GM-K562 Cell Vaccine - Drug Profile 222
P-1446 - Drug Profile 224
DI-B4 - Drug Profile 226
8-chloroadenosine - Drug Profile 227
IMMU-114 - Drug Profile 228
ciclopirox olamine - Drug Profile 229
CD19.CAR-CD28Z T Cells - Drug Profile 230
exatecan mesylate - Drug Profile 231
Kappa CD28 T Cells - Drug Profile 233
marizomib - Drug Profile 234
ublituximab - Drug Profile 236
plerixafor - Drug Profile 238
ocaratuzumab - Drug Profile 240
LY-2874455 - Drug Profile 242
BMN-673 - Drug Profile 243
RG-7593 - Drug Profile 245
polatuzumab vedotin - Drug Profile 247
AMG-319 - Drug Profile 249
CC-115 - Drug Profile 250
KPT-330 - Drug Profile 251
Gene Modified T Cells for Leukemia - Drug Profile 253
TGR-1202 - Drug Profile 255
TG-1101 + TGR-1202 - Drug Profile 256
INCB-040093 - Drug Profile 257
Oncoquest-CLL Vaccine - Drug Profile 258
GDC-0853 - Drug Profile 259
ACP-196 - Drug Profile 260
bendamustine hydrochloride SI - Drug Profile 261
rituximab biosimilar - Drug Profile 262
CST-103 - Drug Profile 263
CVA-21 - Drug Profile 264
silmitasertib - Drug Profile 268
rituximab biosimilar - Drug Profile 270
Vivia-007 - Drug Profile 272
Vivia-008 - Drug Profile 273
Vivia-1615 - Drug Profile 274
Vivia-577 - Drug Profile 275
rituximab biosimilar - Drug Profile 276
ofatumumab biosimilar - Drug Profile 277
IGN-523 - Drug Profile 278
IGN-786 - Drug Profile 279
PRT-060318 - Drug Profile 280
Ritonavir Analogs - Drug Profile 281
OP-449 - Drug Profile 282
4A5 - Drug Profile 284
Monoclonal Antiobody to Inhibit ROR-1 cells for Chronic Lymphocytic Leukemia - Drug Profile 285
GNR-022 - Drug Profile 286
Monoclonal Antibodies To Inhibit ROR-1 For Chronic Lymphocytic Leukemia - Drug Profile 287
MSK-777 - Drug Profile 288
FB-811 - Drug Profile 290
rituximab biosimilar - Drug Profile 291
LDC-2636 - Drug Profile 292
HCQ/CLB-Loaded anti-CD20 BNP - Drug Profile 293
rituximab biosimilar - Drug Profile 294
OSU-2S - Drug Profile 295
HMPL-523 - Drug Profile 296
rituximab biosimilar - Drug Profile 297
LG-768 - Drug Profile 298
ABT-737 - Drug Profile 299
Small Molecules To Inhibit ROR-1 - Drug Profile 301
rituximab biosimilar - Drug Profile 302
Anti-CD38 - Drug Profile 303
APR-246 Analogues - Drug Profile 304
Small Molecule to Inhibit BTK for Cancer - Drug Profile 305
Antibody to Inhibit CD62L for CLL - Drug Profile 306
FIB-114 - Drug Profile 307
Small Molecules to Inhibit Beta Catenin for Chronic Lymphocytic Leukemia - Drug Profile 308
Small Molecules to Inhibit CDK9 for Chronic Lymphocytic Leukaemia - Drug Profile 309
rituximab biosimilar - Drug Profile 310
Small Molecule for Hematologic Malignancies - Drug Profile 311
Drug For Chronic Lymphocytic Leukemia - Drug Profile 312
hA19 Antibody - Drug Profile 313
KAN-0439365 - Drug Profile 314
Compound-1 - Drug Profile 315
Compound-22 - Drug Profile 316
VDAC1 Based Peptides For Cancer - Drug Profile 317
Demibodies for Chronic Lymphocytic Leukemia - Drug Profile 318
blinatumomab - Drug Profile 319
ublituximab - Drug Profile 322
rituximab biosimilar - Drug Profile 324
rituximab biosmiliar - Drug Profile 325
rituximab biosimilar - Drug Profile 326
rituximab biosimilar - Drug Profile 327
Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 328
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 416
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 417
Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 418
Featured News & Press Releases 418

Appendix 425
Methodology 425
Coverage 425
Secondary Research 425
Primary Research 425
Expert Panel Validation 425
Contact Us 426
Disclaimer 426

List of Table


Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2014 22
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2014 23
Number of Products under Development by Companies, H1 2014 25
Number of Products under Development by Companies, H1 2014 (Contd..1) 26
Number of Products under Development by Companies, H1 2014 (Contd..2) 27
Number of Products under Development by Companies, H1 2014 (Contd..3) 28
Number of Products under Development by Companies, H1 2014 (Contd..4) 29
Number of Products under Development by Companies, H1 2014 (Contd..5) 30
Number of Products under Investigation by Universities/Institutes, H1 2014 32
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 33
Comparative Analysis by Late Stage Development, H1 2014 34
Comparative Analysis by Clinical Stage Development, H1 2014 35
Comparative Analysis by Early Stage Development, H1 2014 36
Comparative Analysis by Unknown Stage Development, H1 2014 37
Products under Development by Companies, H1 2014 38
Products under Development by Companies, H1 2014 (Contd..1) 39
Products under Development by Companies, H1 2014 (Contd..2) 40
Products under Development by Companies, H1 2014 (Contd..3) 41
Products under Development by Companies, H1 2014 (Contd..4) 42
Products under Development by Companies, H1 2014 (Contd..5) 43
Products under Investigation by Universities/Institutes, H1 2014 44
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H1 2014 45
Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 46
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amgen Inc., H1 2014 47
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H1 2014 48
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eli Lilly and Company, H1 2014 49
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Viralytics Ltd., H1 2014 50
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genentech, Inc., H1 2014 51
Chronic Lymphocytic Leukemia (CLL) - Pipeline by MedImmune, LLC, H1 2014 52
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences, Inc., H1 2014 53
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 54
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Emergent BioSolutions Inc., H1 2014 55
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lentigen Corporation, H1 2014 56
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amorfix Life Sciences Ltd., H1 2014 57
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Piramal Enterprises Limited, H1 2014 58
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celltrion, Inc., H1 2014 59
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H1 2014 60
Chronic Lymphocytic Leukemia (CLL) - Pipeline by BioMarin Pharmaceutical Inc., H1 2014 61
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Richter Gedeon Nyrt., H1 2014 62
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 63
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genmab A/S, H1 2014 64
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals Inc., H1 2014 65
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H1 2014 66
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 67
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bayer AG, H1 2014 68
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H1 2014 69
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck KGaA, H1 2014 70
Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2014 71
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celldex Therapeutics, Inc., H1 2014 72
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H1 2014 73
Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H1 2014 74
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 75
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Mundipharma International Limited, H1 2014 76
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Senesco Technologies, Inc., H1 2014 77
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Panacea Biotec Limited, H1 2014 78
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Simcere Pharmaceutical Group, H1 2014 79
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hybrigenics S.A., H1 2014 80
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 81
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Memgen, LLC., H1 2014 82
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H1 2014 83
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Altor BioScience Corporation, H1 2014 84
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics, Inc., H1 2014 85
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Grupo Ferrer Internacional, S.A., H1 2014 86
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Onconova Therapeutics, Inc., H1 2014 87
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Angstrom Pharmaceuticals, Inc., H1 2014 88
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2014 89
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aprea AB, H1 2014 90
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biothera, Inc., H1 2014 91
Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB Biotechnologies, S.A.S, H1 2014 92
Chronic Lymphocytic Leukemia (CLL) - Pipeline by KAEL-GemVax Co., Ltd., H1 2014 93
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biosidus S.A., H1 2014 94
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Fountain Biopharma Inc., H1 2014 95
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Igenica, Inc., H1 2014 96
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aprogen, Inc., H1 2014 97
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2014 98
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Vivia Biotech, S.L., H1 2014 99
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lead Discovery Center GmbH, H1 2014 100
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kancera AB, H1 2014 101
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Conkwest, Inc., H1 2014 102
Chronic Lymphocytic Leukemia (CLL) - Pipeline by International Biotechnology Center Generium, H1 2014 103
Chronic Lymphocytic Leukemia (CLL) - Pipeline by MENTRIK Biotech, LLC, H1 2014 104
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Rhizen Pharmaceuticals SA, H1 2014 105
Chronic Lymphocytic Leukemia (CLL) - Pipeline by bioXPRESS Therapeutics SA, H1 2014 106
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tolero Pharmaceuticals, Inc., H1 2014 107
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innovent Biologics, Inc., H1 2014 108
Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H1 2014 109
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2014 110
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amgen Astellas BioPharma K.K., H1 2014 111
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Senhwa Biosciences, H1 2014 112
Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pharmapraxis, H1 2014 113
Assessment by Monotherapy Products, H1 2014 114
Assessment by Combination Products, H1 2014 115
Number of Products by Stage and Target, H1 2014 118
Number of Products by Stage and Mechanism of Action, H1 2014 125
Number of Products by Stage and Route of Administration, H1 2014 132
Number of Products by Stage and Molecule Type, H1 2014 135
Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H1 2014 337
Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2014 425
Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2014 426

List of Chart


Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2014 22
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2014 23
Number of Products under Development by Companies, H1 2014 24
Number of Products under Investigation by Universities/Institutes, H1 2014 31
Comparative Analysis by Late Stage Development, H1 2014 34
Comparative Analysis by Clinical Stage Development, H1 2014 35
Comparative Analysis by Early Stage Products, H1 2014 36
Assessment by Monotherapy Products, H1 2014 114
Number of Products by Top 10 Target, H1 2014 116
Number of Products by Stage and Top 10 Target, H1 2014 117
Number of Products by Top 10 Mechanism of Action, H1 2014 123
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 124
Number of Products by Top 10 Route of Administration, H1 2014 130
Number of Products by Stage and Top 10 Route of Administration, H1 2014 131
Number of Products by Top 10 Molecule Type, H1 2014 133
Number of Products by Stage and Top 10 Molecule Type, H1 2014 134

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *